[原发性皮肤B细胞淋巴瘤中的抗CD20抗体。皮肤病患者的初步结果]

[Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].

作者信息

Gellrich S, Muche J M, Pelzer K, Audring H, Sterry W

机构信息

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie mit Asthmapoliklinik, Schumannstrasse 20/21, 10117 Berlin.

出版信息

Hautarzt. 2001 Mar;52(3):205-10. doi: 10.1007/s001050051291.

DOI:10.1007/s001050051291

PMID:11284065

Abstract

BACKGROUND AND OBJECTIVE

Primary cutaneous B cell lymphomas (pCBCL) are rare extra-cutaneous non-Hodgkin lymphomas which occur on the trunk as follicle center cell lymphoma or on the leg as large B cell lymphoma. The currently accepted therapy of pCBCL (excision and/or radiotherapy, systemic interleukin 2 and interferon alpha 2a, local injection of cisplatin or multiagent chemotherapy, i.e. CHOP) is insufficient for treatment of multifocal pCBCL and secondary extracutaneous involvement. For this reason, the new synthetic chimeric, monoclonal anti-CD20 antibody Rituximab is an alternative treatment for patients with pCBCL.

PATIENTS/METHODS: Four patients with pCBCL localized to the trunk or head were treated with Rituximab (375 mg/kg weekly for 4-8 weeks, then maintenance therapy every 4 weeks for 6 months).

RESULTS

All 4 patients showed a response (2/4 partial; 2/4 complete). Side effects were minimal.

CONCLUSIONS

Rituximab is an alternative immunotherapeutic drug for the treatment of pCBCL. Our initial experience with this new modality are presented and discussed.

摘要

背景与目的

原发性皮肤B细胞淋巴瘤（pCBCL）是罕见的皮肤外非霍奇金淋巴瘤，可发生于躯干，表现为滤泡中心细胞淋巴瘤，或发生于腿部，表现为大B细胞淋巴瘤。目前公认的pCBCL治疗方法（切除和/或放疗、全身使用白细胞介素2和干扰素α2a、局部注射顺铂或多药化疗，即CHOP方案）对于治疗多灶性pCBCL和继发性皮肤外受累是不够的。因此，新型合成嵌合单克隆抗CD20抗体利妥昔单抗是pCBCL患者的一种替代治疗方法。

患者/方法：4例局限于躯干或头部的pCBCL患者接受了利妥昔单抗治疗（375mg/kg，每周1次，共4 - 8周，然后每4周进行维持治疗，持续6个月）。